TWIST: Time Restricted Eating for Weight Loss Maintenance

Sponsor
NYU Langone Health (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05742165
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
50
1
2
14
3.6

Study Details

Study Description

Brief Summary

The aim of this pilot feasibility and acceptability, randomized clinical trial will be to examine the effects of two-time restricted eating (TRE) interventions on weight loss maintenance (WLM). This study will be conducted in 40 individuals with non-surgical weight loss of ≥5% initial body weight recruited from the NYU Langone Health Weight Management Program and NY-MOVE! Weight Management Clinic at the Manhattan VA. Measurements will occur at baseline, 4 and 12 weeks. Participants will be randomized with equal allocation to 2 groups: (1) TRE6 or (2) TRE10. The TRE6 will restrict their eating window to 6 hours per day and the TRE10 to 10 hours per day.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Time Restricted Eating (TRE)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Time Restricted Eating for Weight Loss Maintenance (TWIST): A Single-Site, Pilot Feasibility and Acceptability Randomized Clinical Trial in Adults With Recent Weight Loss
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Time-Restricted Eating - 6 Hours (TRE6)

Participants will be instructed to consume all daily food and beverages during their allotted 6-hour time period.

Behavioral: Time Restricted Eating (TRE)
TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.

Experimental: Time-Restricted Eating - 10 Hours (TRE10)

Participants will be instructed to consume all daily food and beverages during their allotted 10-hour time period.

Behavioral: Time Restricted Eating (TRE)
TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.

Outcome Measures

Primary Outcome Measures

  1. Retention Rate [Up to Week 12]

    Percentage of participants who complete all study visits. Measure of feasibility.

  2. Recruitment Rate [Up to Week 12]

    Number of individuals who must be approached to enroll one participant in the study. A recruitment funnel will be developed by documenting the total number of eligible patients completing the NYU Langone Health-WMP and NY- MOVE! programs losing ≥5% of their baseline body weight.

  3. TRE Experience Questionnaire (TRE-EQ) Score [Week 12]

    Online questionnaire that includes 5-point scaled items (0=strongly disagree, 5=strongly agree) regarding difficulties encountered with hunger and appetite; eating within the assigned window; coordinating the TRE window with work, school and home demands; and accommodating social connections (e.g., behaviors and preferences of fellow diners).

  4. Adherence Rate [Up to Week 12]

    Using data from participant-worn ActiGraphs and on eating patterns, a day will be labeled "adherent" if all eating occasions (food or beverage with caloric value) are measured inside (± 30 minutes) their prescribed eating window. Adherence rate will be calculated by dividing the total number of adherent days by the total number of days with a logged eating occasion.

Secondary Outcome Measures

  1. Change from Baseline in Lean Mass [Baseline, Week 12]

    Measured using Bioelectrical Impedance Analysis (BIA). Expressed in kilograms.

  2. Change from Baseline in Fat Mass [Baseline, Week 12]

    Measured using BIA. Expressed in kilograms.

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥5% non-surgical weight loss from NYULH-WMP and NY-MOVE! Endocrinology Weight Management Clinic in the last 3 months

  • BMI between 20.5 - 45 m/kg2

  • between the ages 25 to 65 years old

  • own a smartphone or willing to use a smartphone if provided for self-monitoring

  • Eating window >12 h per day

  • <150 mins/wk of physical activity

  • log at least 2 meals into the smartphone app on ≥5 days

Exclusion Criteria:
  • <25 years or >65 years of age

  • Body weight in excess of 400lbs (181.4kg)

  • pregnant, trying to get pregnant or breastfeeding

  • previous or planned bariatric surgery

  • previous or current history of eating disorder

  • ongoing participation in another weight-management research study

  • continued participation in a weight loss program other than the proposed study

  • currently on appetite suppressants

  • currently following intermittent fasting or skipping meals

  • eating window <11h 59min/day

  • perform overnight shift work more than once a week

  • work that includes travel across one or more time zones

  • currently on anti-obesity medications (AOMs) such as, GLP-1 analogues (exenatide, tirzepatide, semaglutide, liraglutide) and pancreatic lipase inhibitors (Orlistat/Xenical and Alli)

  • prescribed medications expected to result in weight loss such as Orlistat, Naltrexone, Bupropion, Lorcaserin, Phentermine, Topiramate, or Liraglutide, and who are unwilling to delay treatment with these medications for the next 3 months

  • unable or unwilling to provide informed consent

  • unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment)

  • unwilling to accept randomization assignment

  • unable to log at least 2 meals into the smartphone app on ≥5 d during the screening period

  • have type 1 or other conditions that would preclude restricted eating windows

  • have type 2 diabetes with a HbA1c >7.0% on medications except for metformin alone

  • narcolepsy

  • active cancer

  • organ dysfunction

  • current steroid use

  • daytime sleepiness with the Epworth Sleepiness Scale >10

  • severe insomnia with a score ≥15 on the Insomnia Severity Index

  • 2.5 kg additional weight loss during run-in phase (weight regain is not an exclusion criteria)

Contacts and Locations

Locations

Site City State Country Postal Code
1 NYU Langone Health New York New York United States 10016

Sponsors and Collaborators

  • NYU Langone Health
  • National Heart, Lung, and Blood Institute (NHLBI)

Investigators

  • Principal Investigator: Mary A. Sevick, ScD, NYU Langone Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
NYU Langone Health
ClinicalTrials.gov Identifier:
NCT05742165
Other Study ID Numbers:
  • 22-01453
First Posted:
Feb 23, 2023
Last Update Posted:
Feb 23, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by NYU Langone Health
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2023